6,810 Shares in Neurocrine Biosciences, Inc. $NBIX Acquired by Winnow Wealth LLC

Winnow Wealth LLC acquired a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the third quarter, according to its most recent filing with the SEC. The firm acquired 6,810 shares of the company’s stock, valued at approximately $960,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in NBIX. JPMorgan Chase & Co. increased its position in Neurocrine Biosciences by 59.6% in the second quarter. JPMorgan Chase & Co. now owns 4,261,747 shares of the company’s stock worth $535,659,000 after purchasing an additional 1,590,749 shares during the period. Norges Bank bought a new position in shares of Neurocrine Biosciences in the 2nd quarter valued at about $122,278,000. Los Angeles Capital Management LLC grew its position in shares of Neurocrine Biosciences by 19,454.9% during the 2nd quarter. Los Angeles Capital Management LLC now owns 744,650 shares of the company’s stock worth $93,595,000 after buying an additional 740,842 shares during the period. AQR Capital Management LLC raised its stake in shares of Neurocrine Biosciences by 40.5% during the second quarter. AQR Capital Management LLC now owns 1,510,015 shares of the company’s stock worth $189,794,000 after buying an additional 435,385 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. acquired a new position in Neurocrine Biosciences in the second quarter valued at approximately $42,933,000. 92.59% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Leslie V. Norwalk sold 1,190 shares of the stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $155.09, for a total transaction of $184,557.10. Following the completion of the transaction, the director owned 6,239 shares in the company, valued at approximately $967,606.51. This represents a 16.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Darin Lippoldt sold 4,376 shares of Neurocrine Biosciences stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $159.65, for a total value of $698,628.40. Following the completion of the sale, the insider directly owned 43,405 shares in the company, valued at $6,929,608.25. This represents a 9.16% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 80,266 shares of company stock valued at $11,400,517 over the last three months. Insiders own 4.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on NBIX shares. UBS Group dropped their target price on shares of Neurocrine Biosciences from $188.00 to $178.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Stifel Nicolaus upped their price objective on Neurocrine Biosciences from $183.00 to $188.00 and gave the company a “buy” rating in a report on Thursday, December 11th. HC Wainwright increased their target price on Neurocrine Biosciences from $168.00 to $198.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Needham & Company LLC boosted their target price on Neurocrine Biosciences from $170.00 to $184.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Neurocrine Biosciences in a research report on Thursday, January 22nd. Seventeen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $174.25.

Neurocrine Biosciences Price Performance

NASDAQ NBIX opened at $136.06 on Friday. Neurocrine Biosciences, Inc. has a one year low of $84.23 and a one year high of $160.18. The firm has a market cap of $13.57 billion, a P/E ratio of 32.55, a P/E/G ratio of 0.73 and a beta of 0.28. The stock’s 50-day moving average is $143.13 and its 200-day moving average is $140.19.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Tuesday, October 28th. The company reported $2.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.59. The business had revenue of $794.90 million during the quarter, compared to analyst estimates of $746.61 million. Neurocrine Biosciences had a return on equity of 15.82% and a net margin of 15.95%.Neurocrine Biosciences’s quarterly revenue was up 27.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.81 EPS. Equities analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.